12 new development(s) in neoantigen vaccines today.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma. Adding intismeran autogene, an mRNA-based individualized neoantigen therapy also known as a personalized cancer vaccine, to adjuvant pem…
Danish clinical-stage techbio Evaxion (Nasdaq: EVAX) has announced new three-year immune and clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma, with the news sending the firm’s share up almost 9% to $3.71 in pre-market trading. The da…
On October 22 US Eastern Time, Moderna’s stock plunged 20.14% despite its Phase III trial for the personalized cancer vaccine Intismeran autogene meeting primary efficacy endpoints. The drop reflected a "sell the news" reaction following a sharp prior run-up and investor scrutiny…
Log in to our secure, personalized website to manage your care (formerly myMDAnderson). If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start. Gi…
Follow this section to personalize your feed and get instant alerts. Update your preferences in Account Settings Follow this tag to personalize your feed and get instant alerts. Update your preferences in Account Settings Follow this author to personalize your feed and get instan…
When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were exhilarated. And that was before its makers had even disclosed just how well the therapy w…
Moderna shares dropped as much as 25% on Thursday following the leak of partial data on its closely watched cancer vaccine developed with Merck. Shares of both drugmakers fell even though the data, released in full later Thursday following the leak, appeared meaningful for patien…
WASHINGTON (AP) — A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients' tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck. The vaccine was custom-brewed for each patient to match th…
Data for Merck and Moderna’s highly anticipated personalized cancer vaccine leaked online Thursday morning, days ahead of a headlining reveal at the European Society of Medical Oncology meeting in Spain. The results left analysts disappointed—and hoping that the real presentation…
SA Spotlight uses AI to summarize content published on Seeking Alpha. All summaries are reviewed by human editors prior to publication. Moderna (MRNA) shares tumbled about 17% on Thursday after leaked clinical data from the company's personalized cancer vaccine program triggered …
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer The Malaysian Reserve
Relevant work from earlier we're still surfacing — not today's news.